Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion

Drug Metabolism and Disposition

Volumn 37, Issue 7, 2009, Pages 1448-1455

  Perfetti, Ximena ^a,b   O'Mathúna, Brian ^a,b   Pizarro, Nieves ^a   Cuyàs, Elisabet ^a,d   Khymenets, Olha ^a,b   Almeida, Bruno ^a,b,c   Pellegrini, Manuela ^d,f   Pichini, Simona ^f   Lau, Serrine S ^e   Monks, Terrence J ^e   Farré, Magí ^a   Pascual, Jose Antonio ^a   Joglar, Jesús ^c   De La Torre, Rafael ^a,b  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITY OF ARIZONA   (United States)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYL ALPHA METHYLDOPAMINE; 3,4 DIHYDROXYAMPHETAMINE; 3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 (N ACETYLCYSTEIN S YL) 3,4 DIHYDROXYAMPHETAMINE; 5 (N ACETYLCYSTEIN S YL) 3,4 DIHYDROXYMETHAMPHETAMINE; ACETYLCYSTEINE; AMPHETAMINE DERIVATIVE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6; GLUTATHIONE; SULFIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY CONCENTRATING CAPACITY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; URINALYSIS; VALIDATION STUDY;

ADULT; EATING; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SULFIDES; URINE; YOUNG ADULT;

ANIMALIA; RATTUS;

EID: 67649389513     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.026393     Document Type: Article

References (33)

1. 1A receptors in rats. Eur J Pharmacol 281:101-105.
2. Bai F, Lau SS, and Monks TJ (1999) Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem Res Toxicol 12:1150-1157. (Pubitemid 30013524)
3. Bai F, Jones DC, Lau SS, and Monks TJ (2001) Serotonergic neurotoxicity of 3,4- (±)methylenedioxyamphetamine and 3,4-(±)- methylendioxymethamphetamine (Ecstasy) is potentiated by inhibition of γ-glutamyl transpeptidase. Chem Res Toxicol 14:863-870. (Pubitemid 32661342)
4. Barrionuevo M, Aguirre N, Del Río JD, and Lasheras B (2000) Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA. Pharmacol Biochem Behav 65:233-240. (Pubitemid 30100268)
5. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, and Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289-293. (Pubitemid 36249683)
6. Cadet JL, Krasnova IN, Jayanthi S, and Lyles J (2007) Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11:183-202.
7. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, et al. (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in post-mortem human brain. Am J Hum Genet 75:807-821. (Pubitemid 39390488)
8. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, and Camí J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26:137-144. (Pubitemid 38501207)
9. de la Torre R and Farré M (2004) Neurotoxicity of MDMA (Ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25:505-508. (Pubitemid 39233561)
10. Elce JS (1972) Metabolism of a glutathione conjugate of 2-hydroxyoestradiol-17 in the adult male rat. Biochem J 126:1067-1071.
11. Erives GV, Lau SS, and Monks TJ (2008) Accumulation of neurotoxic thioether metabolites of 3,4-(±)-methylenedioxymethamphetamine in rat brain. J Pharmacol Exp Ther 324:284-291. (Pubitemid 350294185)
12. Goñi-Allo B, Puerta E, Mathúna BO, Hervias I, Lasheras B, de la Torre R, and Aguirre N (2008a) On the role of tyrosine and peripheral metabolism in the 3,4-methyelendioxymethamphetamine-induced serotonin neurotoxicity in rats. Neuropharmacology 54:885-900.
13. Goñi-Allo B, O Mathúna B, Segura M, Puerta E, Lasheras B, de la Torre R, and Aguirre N (2008b) The relationship between core body temperature and 3,4-methyelendioxymethamphetamine metabolism in rats: implications for neurotoxicity. Psychopharmacology 197:263-278.
14. Green AR, Mechan AO, Elliott JM, O'Shea E, and Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 55:463-508. (Pubitemid 37013213)
15. Hill BA, Davison KL, Dulik DM, Monks TJ, and Lau SS (1994) Metabolism of 2-(glutathion-S-yl)hydroquinone and 2,3,5-(triglutathion-S-yl)hydroquinone in the in situ perfused rat kidney: relationship to nephrotoxicity. Toxicol Appl Pharmacol 129:121-132. (Pubitemid 24352629)
16. Hiramatsu M, Kumagai Y, Unger SE, and Cho AK (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254:521-527. (Pubitemid 20262091)
17. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, de la Torre R, and Monks TJ (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313:422-431. (Pubitemid 40411369)
18. Jones DC, Lau SS, and Monks TJ (2004) Thioether metabolites of 3,4-(±)-methylenedioxyamphetamine and 3,4-(±)- methylenedioxymethamphetamine inhibit hSERT function and simultaneously stimulate dopamine uptake into hSERT expressing SK-N-MC cells. J Pharmacol Exp Ther 311:298-306. (Pubitemid 39287809)
19. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, and Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112-113:133-142. (Pubitemid 30138114)
20. Miller RT, Lau SS, and Monks TJ (1996) Effects of intra cerebroventricular administration of 5-(glutathion-S-yl)-α-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. Chem Res Toxicol 9:457-465. (Pubitemid 26082970)
21. Miller RT, Lau SS, and Monks TJ (1997) 2,5-Bis-(glutathion-S-yl)-α- methyldopamine, a putative metabolite of (±)-3,4- methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 323:173-180. (Pubitemid 27152268)
22. Monks TJ, Jones DC, Bai F, and Lau SS (2004) The role of metabolism in 3,4-(±)-methylenedioxyamphetamine and 3,4-(±)- methylenedioxymethamphetamine (Ecstasy) toxicity. Ther Drug Monit 26:132-136. (Pubitemid 38501206)
23. Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens: identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305-313.
24. O'Mathúna B, Farré M, Rostami-Hodjegan A, Yang J, Cuyàs E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, et al. (2008) The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol 28:523-529.
25. Parrott AC (2002) Recreational Ecstasy/MDMA, the serotonin syndrome and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837-844. (Pubitemid 34219233)
26. Pizarro N, Ortuño J, Farré M, Hernández-López C, Pujadas M, Llebaria A, Joglar J, Roset PN, Mas M, Segura J, et al. (2002) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157-165. (Pubitemid 34309726)
27. Ricaurte GA, Yuan J, and McCann UD (2000) (±)3,4- Methylenedioxymethamphetamine ("Ecstasy")-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42:5-10. (Pubitemid 30436310)
28. Rivera MI, Hinojosa LM, Hill BA, Lau SS, and Monks TJ (1994) Metabolism and toxicity of 2-bromo-(diglutathion-S-yl)-hydroquinone and 2-bromo-3-(glutathion-S-yl)hydroquinone in the in situ perfused rat kidney. Drug Metab Dispos 22:503-510. (Pubitemid 24244857)
29. Schmid B, Bircher J, Preisig R, and Küpfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624. (Pubitemid 16124372)
30. Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42:107-121. (Pubitemid 36188552)
31. Segura M, Farré M, Pichini S, Peiró AM, Roset PN, Ramírez A, Ortuño J, Pacifici R, Zuccaro P, Segura J, et al. (2005) Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 44:649-660. (Pubitemid 40994090)
32. Stone DM, Johnson M, Hanson GR, and Gibb JW (1988) Role of endogenous dopamine in the central serotonergic deficits induces by methylenedioxymethamphetamine. J Pharmacol Exp Ther 247:79-87. (Pubitemid 18253684)
33. Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, and Rostami-Hodjegan A (2006) Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 20:842-849. (Pubitemid 44622750)